 |
 |
 |
|
 | |||||
| |||||||||
 | |||||||||
|
FDA Workshop on Clinical Trial Endpoints in Acute Leukemia The U.S. Food and Drug Administration (FDA) is holding a public workshop on clinical endpoints in acute leukemia. The workshop will discuss clinical trial endpoints that have not been generally accepted but have potential utility for the measurement of clinical benefit or the prediction of clinical benefit with reasonable likelihood for the following disease entities:
Issues identified in the
workshops will be further discussed before the
Oncologic Drugs Advisory Committee (ODAC) and thereafter will be
detailed in FDA Guidance Documents.
Date created: September 21, 2005 |
||||||
 | ||||||
|
||||||
